Table 2

Clinical and laboratory characteristics of patients with 55 first pregnancies observed following registry recruitment, by pregnancy outcomes

N=55 pregnanciesTLDPTLD*PTLD†FD‡FD§EPL
>37.0 weeks34.0–36.6 weeks<34.0 weeks>20.0 weeks10.0–19.6 weeks<10.0 weeks
n: 26n:4n:5n:2n:3n:15
47%7%9%4%5%27%
Additional pregnancy morbidity
 SGA and PECNR1**NRNRNRNR
 SGA1NR1‡‡NRNRNR
 PECNR2††2§§NRNRNR
 PINRNRNRNRNRNR
History of SLE¶¶6 (23%)2 (50%)1 (20%)1 (50%)1 (33%)3 (20%)
History of thrombosis13 (50%)2 (50%)5 (100%)1 (50%)1 (33%)10 (67%)
 Arterial5 (19%)1 (20%)1 (7%)
 Venous10 (38%)24 (80%)1 (50%)1 (33%)10 (67%)
 Arterial and venous2 (8%)1 (7%)
History of pregnancy21 (81%) 1 (25%)4 (80%)1 (33%)11 (73%)
History of pregnancy morbidity15 (58%) 1 (25%)4 (80%)1 (33%)9 (60%)
 ≥1 fetal death >10 weeks10 (38%)2 (40%)6 (40%)
 ≥1 preterm delivery <34 weeks4 (15%)4 (27%)
 ≥1 (pre)-embryonic loss <10 weeks7 (27%)2 (40%)5 (33%)
Laboratory category
 LA (+) only¶9 (35%)2 (50%)2 (40%)1 (50%)1 (33%)2 (13%)
 Double aPL (+)6 (23%)1 (20%)1 (50%)2 (67%)7 (47%)
 Triple aPL (+)9 (35%)2 (50%)2 (40%)5 (33%)
Treatment during pregnancy
 No LDA/LMWH1 (33%)6 (40%)
 LDA alone2 (8%)1 (33%)2 (13%)
 LMWH alone5 (19%)1 (33%)
 LDA+LMWH19 (73%)4 (100%)5 (100%)2 (100%)7 (47%)
 Hydroxychloroquine17 (65%)2 (50%)2 (40%)1 (33%)5 (33%)
Hypertension1 (4%)1 (7%)
Obesity4 (15%)3 (60%)3 (20%)
  • *One spontaneous PTLD, GA 34 weeks.

  • †Two spontaneous PTLD, GA 32 weeks and 33 weeks respectively.

  • ‡Two fetal deaths associated with anomalies: 1 triple X syndrome (47 XXX) at 21 weeks, 1 cystic fibrosis at 20 weeks.

  • §1/3 morphologically normal, 2/3 fetal loss of unknown fetal status.

  • ¶aCL and aβ2GPI not tested in two pregnancies; aβ2GPI not tested in three pregnancies.

  • **GA at 36 weeks.

  • ††GA 35 weeks and 36.4 weeks.

  • ‡‡GA 24 weeks.

  • §§GA 33.6 weeks and 26 weeks.

  • ¶¶pregnancy outcomes in 14 patients with SLE were 6 for TLD (1 SGA), 3 PTLD ((2 PEC at GA 36.4 weeks and 26 weeks), 2 FD (GA 20 weeks and 12 weeks), and 3 EPL.

  • aCL, anticardiolipin antibody; aβ2GPI, anti-β2 glycoprotein-I; EPL, early pregnancy loss; FD, fetal death; GA, gestational age; LA, lupus anticoagulant; LDA, low-dose aspirin; LMWH, low-molecular-weight heparin; NR, not reported; PEC, pre-eclampsia; PI, placental insufficiency; PTLD, preterm live delivery; SGA, small-for-gestational age; TLD, term live delivery.